No profile data available.
Design Therapeutics, Inc. (DSGN) is a healthcare company in the brain and nerve treatment drugs industry, based in Carlsbad, United States, with about 55 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$69.79 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $729.08 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Design Therapeutics reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$729.08 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Alto Neuroscience, Inc. (ANRO), Annexon, Inc. (ANNX), Solid Biosciences Inc. (SLDB), Bright Minds Biosciences Inc. (DRUG).